Gene · 1105
Papers1,932
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 1,932
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts. | Front Immunol | 2022 | 36700205 | PubTator, text mining | PubMed |
| The Role of PARP1 and PAR in ATP-Independent Nucleosome Reorganisation during the DNA Damage Response. | Genes (Basel) | 2022 | 36672853 | PubTator, text mining | PubMed |
| Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. | Cancers (Basel) | 2022 | 36612019 | PubTator, text mining | PubMed |
| Identification of Signature Genes in the PD-1 Relative Gastric Cancer Using a Combined Analysis of Gene Expression and Methylation Data. | J Oncol | 2022 | 36568638 | PubTator, text mining | PubMed |
| The Antioxidant and In Vitro Wound Healing Activity of Cotyledon orbiculata Aqueous Extract and the Synthesized Biogenic Silver Nanoparticles. | Int J Mol Sci | 2022 | 36555732 | PubTator, text mining | PubMed |
| Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma. | Cancers (Basel) | 2022 | 36551696 | PubTator, text mining | PubMed |
| Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer. | Cancers (Basel) | 2022 | 36551580 | PubTator, text mining | PubMed |
| Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. | Mol Biomed | 2022 | 36539659 | PubTator, text mining | PubMed |
| CHD8 suppression impacts on histone H3 lysine 36 trimethylation and alters RNA alternative splicing. | Nucleic Acids Res | 2022 | 36537238 | PubTator, text mining | PubMed |
| The role of auxiliary domains in modulating CHD4 activity suggests mechanistic commonality between enzyme families. | Nat Commun | 2022 | 36473839 | PubTator, text mining | PubMed |
| ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. | Nat Commun | 2022 | 36435834 | PubTator, text mining | PubMed |
| E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer. | Int J Mol Sci | 2022 | 36430858 | PubTator, text mining | PubMed |
| Complexities of Prostate Cancer. | Int J Mol Sci | 2022 | 36430730 | PubTator, text mining | PubMed |
| Overexpression of Ubiquitin-Conjugating Enzyme E2C Is Associated with Worsened Prognosis in Prostate Cancer. | Int J Mol Sci | 2022 | 36430352 | PubTator, text mining | PubMed |
| The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer. | Int J Mol Sci | 2022 | 36430148 | PubTator, text mining | PubMed |
| Contrast variation SAXS: Sample preparation protocols, experimental procedures, and data analysis. | Methods Enzymol | 2022 | 36410957 | PubTator, text mining | PubMed |
| Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. | Elife | 2022 | 36409067 | PubTator, text mining | PubMed |
| CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells. | Nucleic Acids Res | 2022 | 36408932 | PubTator, text mining | PubMed |
| Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. | Front Immunol | 2022 | 36389756 | PubTator, text mining | PubMed |
| Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy. | Int J Mol Sci | 2022 | 36361605 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1105/papers?page=15